OPEN LABEL, PHASE II PILOT STUDY OF STI571 IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA PTCL REFRACTORY, RESISTANT OR NOT AMENABLE TO CONVENTIONAL THERAPY

Mise à jour : Il y a 5 ans
Référence : EUCTR2006-002658-31

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

- Assessment of safety and tolerability of imatinib mesylate 400 mg bid in the clinical setting of peripheral T-cell lymphomas PTCL ; - Assessment of clinical responses defined as disease stabilization DS , partial remission PR , and complete remission CR .


Critère d'inclusion

  • PERIPHERAL T-CELL LYMPHOMA PTCL EXPRESSING PDGFRA

Liens